Abstract
Through the Part D drug program, Medicare has assumed responsibility for the prescription drug needs of beneficiaries and, consequently, for an important component of mental health treatment: psychotropic drugs. Managing the prescription drug benefits of mentally ill dual eligibles could challenge this new program. Efforts to balance quality assurance and cost-effectiveness will be complicated by this population's vulnerability and high level of health care need, the uncertainties surrounding optimal psychotropic drug use, and the economic incentives of prescription-only insurers. We discuss the details and policy implications of this challenge.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
